What is the difference between SULFASALAZINE and Tofacitinib?

SULFASALAZINE is a Aminosalicylate (IBD) and Tofacitinib is a JAK Inhibitor. They reach a similar treatment goal through different pharmacological mechanisms, which is why one may be tolerated by a patient who could not tolerate the other.

Is Sulfasalazine the same as Xeljanz?

No. Sulfasalazine (SULFASALAZINE) and Xeljanz (Tofacitinib) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, SULFASALAZINE or Tofacitinib?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from SULFASALAZINE to Tofacitinib?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

SULFASALAZINE vs Tofacitinib

Compare SULFASALAZINE (Sulfasalazine) and Tofacitinib (Xeljanz) — clinical data, side effects, and patient experiences.

SULFASALAZINE

Sulfasalazine · Aminosalicylate (IBD)

How it works

Other agent

Approved for

INDICATIONS AND USAGE Sulfasalazine Tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis

and as adjunctive therapy in severe ulcerative colitis

and b) for the prolongation of the remission period between acute attacks of ulcerative colitis.

OralTablet

Tofacitinib

Xeljanz · JAK Inhibitor

How it works

Inhibits Janus kinases JAK1 and JAK3, modulating the signalling of interleukins and interferons involved in immune and inflammatory pathways.

Approved for

Rheumatoid Arthritis

Psoriatic Arthritis

Ulcerative Colitis

FDA: 2012OralTablet, Extended-release tablet

Quick Comparison

SULFASALAZINETofacitinib

Drug Class

Aminosalicylate (IBD)

JAK Inhibitor

Route

Oral

Half-Life

—

FDA Approved

—

2012

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

SULFASALAZINE

Drug Not Working

>10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Condition Worsened

0.1-1%

Hair Loss

0.1-1%

Tofacitinib

Drug Not Working

>10%

Joint Pain

1-10%

Condition Worsened

1-10%

Fatigue

1-10%

Headache

1-10%

Rash

0.1-1%

General Unwellness

0.1-1%

Limb Pain

0.1-1%

FDA Warnings

SULFASALAZINE

WARNINGS Hepatic, Renal, and Hematologic Toxicity or Other Conditions Only after critical appraisal should Sulfasalazine Tablets be given to patients with hepatic or renal damage or blood dyscrasias
Deaths associated with the administration of sulfasalazine have been reported from hypersensitivity reactions, agranulocytosis, aplastic anemia, other blood dyscrasias, renal and liver damage, irreversible neuromuscular and central nervous system changes, and fibrosing alveolitis
The presence of clinical signs such as sore throat, fever, pallor, purpura, or jaundice may be indications of serious blood disorders or hepatotoxicity
Serious Infections Serious infections, including fatal sepsis and pneumonia, have been reported

Tofacitinib

Black Box: Serious infections, mortality, malignancy, MACE, thrombosis
Lymphoma risk

Clinical Trial Data

No head-to-head clinical studies found for SULFASALAZINE vs Tofacitinib.

SULFASALAZINE vs Tofacitinib: What You Should Know

Key Differences

SULFASALAZINE is a Aminosalicylate (IBD), while Tofacitinib belongs to the JAK Inhibitor class. This means they work through different pharmacological mechanisms, which may influence both efficacy and side effect profiles.

Safety Considerations

SULFASALAZINE carries 4 FDA warnings. Tofacitinib carries 2 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

BALSALAZIDE DISODIUM vs SULFASALAZINE→MESALAMINE vs SULFASALAZINE→ADALIMUMAB vs SULFASALAZINE→SULFASALAZINE vs USTEKINUMAB→AZATHIOPRINE vs SULFASALAZINE→METHOTREXATE vs SULFASALAZINE→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

SULFASALAZINE: DailyMed label · FAERS adverse events · ClinicalTrials.gov
Tofacitinib: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

SULFASALAZINE vs Tofacitinib

Compare SULFASALAZINE (Sulfasalazine) and Tofacitinib (Xeljanz) — clinical data, side effects, and patient experiences.

SULFASALAZINE

Sulfasalazine · Aminosalicylate (IBD)

How it works

Other agent

Approved for

INDICATIONS AND USAGE Sulfasalazine Tablets are indicated: a) in the treatment of mild to moderate ulcerative colitis

and as adjunctive therapy in severe ulcerative colitis

and b) for the prolongation of the remission period between acute attacks of ulcerative colitis.

OralTablet

Tofacitinib

Xeljanz · JAK Inhibitor

How it works

Inhibits Janus kinases JAK1 and JAK3, modulating the signalling of interleukins and interferons involved in immune and inflammatory pathways.

Approved for

Rheumatoid Arthritis

Psoriatic Arthritis

Ulcerative Colitis

FDA: 2012OralTablet, Extended-release tablet

Quick Comparison

SULFASALAZINETofacitinib

Drug Class

Aminosalicylate (IBD)

JAK Inhibitor

Route

Oral

Half-Life

—

FDA Approved

—

2012

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

SULFASALAZINE

Drug Not Working

>10%

Joint Pain

1-10%

Fatigue

1-10%

Rash

1-10%

Condition Worsened

0.1-1%

Hair Loss

0.1-1%

Tofacitinib

Drug Not Working

>10%

Joint Pain

1-10%

Condition Worsened

1-10%

Fatigue

1-10%

Headache

1-10%

Rash

0.1-1%

General Unwellness

0.1-1%

Limb Pain

0.1-1%

FDA Warnings

SULFASALAZINE

WARNINGS Hepatic, Renal, and Hematologic Toxicity or Other Conditions Only after critical appraisal should Sulfasalazine Tablets be given to patients with hepatic or renal damage or blood dyscrasias
Deaths associated with the administration of sulfasalazine have been reported from hypersensitivity reactions, agranulocytosis, aplastic anemia, other blood dyscrasias, renal and liver damage, irreversible neuromuscular and central nervous system changes, and fibrosing alveolitis
The presence of clinical signs such as sore throat, fever, pallor, purpura, or jaundice may be indications of serious blood disorders or hepatotoxicity
Serious Infections Serious infections, including fatal sepsis and pneumonia, have been reported

Tofacitinib

Black Box: Serious infections, mortality, malignancy, MACE, thrombosis
Lymphoma risk

Clinical Trial Data

No head-to-head clinical studies found for SULFASALAZINE vs Tofacitinib.

SULFASALAZINE vs Tofacitinib: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.